Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
135.18
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
Why Novo Nordisk Shares Are Trading Higher Tuesday
June 25, 2024
The company's weight loss drug Wegovy has been approved in China, the second most populated country that is estimated to have the world's highest number of overweight individuals, according to...
Via
Benzinga
Novo Nordisk Wins Approval For Its Weight-Loss Drug From China
June 25, 2024
China approved the sale of Novo Nordisk's Wegovy on Tuesday. The drugmaker also announced a $4.1 billion investment in the U.S. Novo Nordisk stock climbed 3.0% to an all-time high this morning.
Via
Talk Markets
European Stocks Dip As US Market Sentiment Sours
June 25, 2024
European stocks declined as U.S. market sentiment soured, with the Stoxx 600 index down 0.41% by mid-morning. Novo Nordisk shares rose 1.5% following the approval of its weight loss treatment in...
Via
Talk Markets
A Closer Look at Novo Nordisk's Options Market Dynamics
June 25, 2024
Via
Benzinga
Why Is Regis (RGS) Stock Up 215% Today?
June 25, 2024
Regis stock is up on Tuesday with heavy trading of RGS shares after it announced a new credit facility to pay of its debts.
Via
InvestorPlace
Jefferies Just Raised Its Price Target on Nvidia (NVDA) Stock
June 25, 2024
Nvidia stock is up on Tuesday after shares of NVDA got an increased price target from Jefferies analysts alongside praise.
Via
InvestorPlace
Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?
June 25, 2024
This is a matchup that the latecomer might not be able to win.
Via
The Motley Fool
NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug
June 25, 2024
Novo Nordisk and Eli Lilly dominate the market for GLP-1 drugs, and are racing ahead to produce more of them.
Via
InvestorPlace
Novo Nordisk Surges Nearly 3% After Weight Loss Drug Wegovy Wins Approval in China
June 25, 2024
Novo Nordisk's weight loss drug Wegovy has received approval in China, representing a notable achievement for the Danish pharmaceutical firm.
Via
Benzinga
Novartis Stock Just Below Innovative Drugmaker's All-Time High; Gets Key Rating Upgrade
June 25, 2024
Novartis stock is in a buy range after moving past a 103.55 entry in a cup with handle. The buy range extends to 5% above the initial entry.
Via
Investor's Business Daily
Wegovy, Ozempic Maker Novo Nordisk To Invest $4.1B In US Manufacturing, Doubling Plant Size To Meet Surging Demand For Weight Loss Drugs
June 25, 2024
Novo Nordisk A/S is set to invest $4.1 billion in expanding its U.S. manufacturing operations to meet the increasing demand for its weight loss drugs.
Via
Benzinga
Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
June 24, 2024
Regeneron Pharmaceuticals released data from a Phase 1 study on garetosmab and trevogrumab at the ADA meeting, showing significant increases in lean mass and reductions in fat mass in healthy...
Via
Benzinga
Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely'
June 24, 2024
Eli Lilly's stock may rise due to supply issues at competitor Novo Nordisk, according to Reddit users. Its weight loss drug and upcoming FDA approval are also factors. Investors are optimistic about...
Via
Benzinga
Exposures
Product Safety
ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings
June 24, 2024
Altimmune (ALT) stock is soaring and trending after the company reported data on its GLP-1 weight-loss drug today.
Via
InvestorPlace
7 Strong Buy Blue-Chip Stocks to Keep You in the Green
June 24, 2024
Consider these seven strong buy blue-chip stocks for steady growth of your investment portfolio, no matter the market situation.
Via
InvestorPlace
Novo Nordisk's Wegovy Demonstrates Greater Weight Loss In Women With Heart Condition
June 24, 2024
The greater weight loss in women did not result in significantly better improvements in heart failure symptoms.
Via
Benzinga
3 Biotech Stocks to Buy Now: June 2024
June 21, 2024
These are the three best biotech stocks to buy for long-term returns and portfolio stability due to their target patient populations,
Via
InvestorPlace
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments.
Via
Benzinga
Lawsuit Could Challenge Trust In Ozempic And Other Popular Weight Loss Drugs
June 21, 2024
Weight loss drug manufacturers Novo Nordisk and Eli Lilly are being challenged in court. The companies are accused of failing to properly warn patients about associated risks.
Via
Talk Markets
Topics
Lawsuit
Exposures
Financial
Legal
The Best Could Be Yet to Come for Novo Nordisk and Ozempic
June 21, 2024
Novo Nordisk's stock may look expensive but not if you focus on the long term.
Via
The Motley Fool
Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss
June 21, 2024
As per the official press release, the 16-week trial aimed to evaluate the safety, tolerability, and clinical effects of the drug called petrelintide.
Via
Benzinga
Nestle Carefully Targets Weight-Loss Drug Users with New Food Line
June 21, 2024
Nestle's new Vital Pursuit brand targets individuals on weight-loss drugs without mentioning medications on packaging, addressing regulatory concerns and focusing on marketing through social media.
Via
Benzinga
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
June 20, 2024
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.
Via
Benzinga
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
June 20, 2024
Eli Lilly & Co has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of...
Via
Benzinga
7 Stocks With Impressive Earnings Growth: Real or Engineered?
June 19, 2024
These growth stocks have shown impressive earnings increases but not all earnings growth is the same so investors must pay attention.
Via
InvestorPlace
Eli Lilly Hits All-Time High, Named To Big Cap 20 List: Check These Lists For Best Stocks To Buy
June 18, 2024
Eli Lilly stock has been on an astounding run. In 2009 its stock sold for 27.21 a share. It closed Tuesday at 891.46, up 3,149% from 2009.
Via
Investor's Business Daily
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
June 18, 2024
We ran a screener using Benzinga Pro to filter out three mega-cap stocks that are currently trading at attractive valuations.
Via
Benzinga
Obesity In Children - US Parents Face Tough Time To Access Recommended Treatment, Though Novo Nordisk's Drug Still Sees Strong Demand
June 18, 2024
U.S. parents face significant barriers to accessing intensive behavioral counseling for childhood obesity, with programs often unavailable, not covered by insurance, and requiring substantial time...
Via
Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
June 18, 2024
This stock may not be a slam dunk, but it's looking very promising.
Via
The Motley Fool
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
June 17, 2024
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.